Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03424603 · ClinicalTrials.gov registry record · Phase 1
Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies
A Phase 1 study, sponsored by Sutro Biopharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 70
- Enrollment target
NCT03424603: Completed Phase 1 study, sponsored by Sutro Biopharma.
NCT03424603 is a Phase 1 study that has completed, run by Sutro Biopharma. The registered enrollment target is 70 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (17% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03424603, a Phase 1 study, has completed, sponsored by Sutro Biopharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 70 participants
- Enrollment target
Study Summary
First-in-human Phase 1 trial to study the safety, pharmacokinetics and preliminary efficacy of STRO-001 given intravenously every 3 weeks.
Primary Outcome
Incidence of adverse events (AEs) observed across STRO-001 dose levels
Interventions
- DRUG STRO-001
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2018-02-22 |
| Est. Completion | 2024-03-15 |
| Phase | Phase 1 |
What the finished NCT03424603 record still lists
NCT03424603 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 70 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (17% higher).
The record links to 0 conditions, and to 1 intervention - of which STRO-001 is the first listed.
NCT03424603 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03424603 about?
NCT03424603 is a clinical study titled "Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies". First-in-human Phase 1 trial to study the safety, pharmacokinetics and preliminary efficacy of STRO-001 given intravenously every 3 weeks.
What is the current status of trial NCT03424603?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 70 participants. The study started on 2018-02-22. Estimated completion is 2024-03-15.
What interventions are being tested in trial NCT03424603?
The interventions under investigation include: STRO-001 (DRUG).
Who is sponsoring clinical trial NCT03424603?
This trial is sponsored by Sutro Biopharma, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03424603's enrollment target sits among peer trials
70 749th of 2000 higher than 1,227 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00969111 · 70 participants · NA
Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy
- NCT01712620 · 70 participants · Phase 2
Spironolactone for Pulmonary Arterial Hypertension
- NCT02143830 · 70 participants · Phase 2
HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
- NCT02601339 · 70 participants
NIRS Monitoring in Premature Infants
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI